03/13/2023
We want to welcome Dyadic International, Inc International, Inc. (NASDAQ: $DYAI) to the ROTH Capital Partners 35th Annual Conference (March 12–14) section of B2i Digital at https://lnkd.in/ezkbqYDD
Dyadic International (Nasdaq: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.
Dyadic’s primary area of focus is on applying its industrially proven fungus Thermothelomyces heterothallica to speed development, lower costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.
Additionally, Dyadic is further developing the Dapibus™ filamentous fungal based microbial protein production platform for the development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
Dyadic is leveraging its microbial platform technologies to enable collaborators to develop effective preventative and therapeutic treatments in developed and emerging countries.
To learn more about the Dyadic C1 Technology, please visit www.dyadic.com.
We look forward to seeing the continued results from Mark Emalfarb, Ronen Tchelet, Ping Wang Rawson, Joe Hazelton the rest of the Dyadic International, Inc. team!
